SCHEMBL4279484

SCHEMBL4279484

Cc1ccc(-n2ccc3cc(Oc4ccnc(Nc5cccc(N)c5)n4)ccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.46
KDR P35968 13/20 0.45
MET P08581 1/20 0.43
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
CDK4 P11802 1/20 0.41
CDK2 P24941 1/20 0.41
SRC P12931 2/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
FLT1 P17948 2/20 0.40
RET P07949 1/20 0.40
FLT3 P36888 2/20 0.40
EGFR P00533 1/20 0.40
BLK P51451 1/20 0.40
SYK P43405 1/20 0.39
GSK3A P49840 1/20 0.39
MAPK14 Q16539 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288896 0.94 CDK5 (0.46) CDK5KDRMETCDK4CDK2
SCHEMBL4288235 0.92 CDK5 (0.45) CDK5KDRMETCDK4CDK2
SCHEMBL4285064 0.92 KDR (0.46) CDK5KDRMETSRCABL1
SCHEMBL4279410 0.91 MET (0.45) CDK5KDRMETKCNH2SCN5A
SCHEMBL4293466 0.91 ABL1 (0.48) CDK5KDRSCN9ASRCABL1
SCHEMBL4280981 0.88 ABL1 (0.48) CDK5KDRMETSRCABL1
SCHEMBL4287061 0.88 CDK5 (0.42) CDK5KDRMETSRCABL1
SCHEMBL4279382 0.87 KDR (0.45) CDK5KDRMETSRCABL1
SCHEMBL4284798 0.87 CDK5 (0.46) CDK5KDRCDK4CDK2SRC
SCHEMBL4287054 0.86 KDR (0.44) CDK5KDRMETSRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 CDK5 113/4885KDR 165/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.